Arbutus Biopharma (ABUS) Current Assets (2010 - 2026)
Arbutus Biopharma (ABUS) posted Current Assets of $277.0 million for Q1 2026, up 193.27% sequentially from $94.5 million in Q4 2025, and up 137.15% YoY from $116.8 million in Q1 2025.
Arbutus Biopharma (ABUS) Current Assets (2010 - 2026) Analysis & Trends
Arbutus Biopharma has reported Current Assets for 17 years, with the latest figure at $277.0 million in Q1 2026.
- Quarterly Current Assets rose 137.15% year-over-year to $277.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $277.0 million (up 137.15% YoY) and the FY2025 annual result came in at $94.5 million, down 25.81% from the prior year.
- Current Assets grew to $277.0 million in Q1 2026 per ABUS's latest filing, from $94.5 million in the prior quarter.
- Over five years, Current Assets peaked at $277.0 million in Q1 2026 and troughed at $94.5 million in Q4 2025.
- A 5-year average of $143.6 million and a median of $141.1 million in 2022 frame the typical range for Current Assets.
- The sharpest annual moves came in 2025 and 2026: Current Assets sank 30.43% in 2025, then soared 137.15% in 2026.
- Over 5 years, Current Assets stood at $151.1 million in 2022, then decreased by 12.65% to $132.0 million in 2023, then decreased by 3.57% to $127.3 million in 2024, then slipped by 25.81% to $94.5 million in 2025, then jumped by 193.27% to $277.0 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $277.0 million, $94.5 million, and $97.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | 273.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 273.88 Mn |
| Mar 31, 2026 | 277.01 Mn |
| Dec 31, 2025 | 94.46 Mn |
| Sep 30, 2025 | 97.44 Mn |
| Jun 30, 2025 | 103.12 Mn |
| Mar 31, 2025 | 116.81 Mn |
| Dec 31, 2024 | 127.32 Mn |
| Sep 30, 2024 | 132.78 Mn |
| Jun 30, 2024 | 148.22 Mn |
| Mar 31, 2024 | 135.87 Mn |
| Dec 31, 2023 | 132.03 Mn |
| Sep 30, 2023 | 141.61 Mn |
| Jun 30, 2023 | 158.80 Mn |
| Mar 31, 2023 | 152.85 Mn |
| Dec 31, 2022 | 151.14 Mn |
| Sep 30, 2022 | 141.14 Mn |
| Jun 30, 2022 | 157.79 Mn |
| Mar 31, 2022 | 172.70 Mn |
| Dec 31, 2021 | 160.66 Mn |
| Sep 30, 2021 | 126.54 Mn |